Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
J Urol. 2021 Jul;206(1):69-79. doi: 10.1097/JU.0000000000001695. Epub 2021 Mar 8.
We hypothesized that differences in active treatment rates may exist according to race/ethnicity in favorable as well as unfavorable intermediate risk prostate cancer.
We relied on the Surveillance, Epidemiology, and End Results 18 database 2010-2015. We stratified according to 3 racial/ethnic groups (White vs Black vs Hispanic) and prostate cancer baseline characteristics (prostate specific antigen, clinical T stage, Gleason group grading, percentage of biopsy cores). We tabulated active treatment rates (radical prostatectomy, external beam radiotherapy) without and with adjustment for baseline age and prostate cancer characteristics.
Baseline prostate specific antigen, clinical T stage, Gleason grade and percentage of positive biopsy cores differed according to racial/ethnic groups in both favorable and unfavorable intermediate risk prostate cancer patients (all p <0.05). Similarly, radical prostatectomy and external beam radiotherapy rates differed according to race/ethnicity in both favorable and unfavorable intermediate risk prostate cancer patients. Radical prostatectomy and external beam radiotherapy rates respectively ranged from 31.7%-41.8% and 26.3%-31.0% in favorable intermediate risk cases and from 33.4%-43.9% and 30.9%-35.5% in unfavorable intermediate risk prostate cancer, across the 3 race/ethnicity groups (both p <0.05). The above heterogeneity in active treatment rates disappeared and marginal differences remained after adjustment for baseline age and prostate cancer characteristics.
Interpretation of active treatment rates in favorable and unfavorable intermediate risk prostate cancer may be severely biased, unless detailed and systematic consideration or adjustment for baseline age and prostate cancer characteristic is enforced.
我们假设在有利和不利的中等风险前列腺癌中,根据种族/族裔,积极治疗率可能存在差异。
我们依赖于监测、流行病学和最终结果 18 数据库 2010-2015。我们根据 3 个种族/族裔群体(白种人 vs 黑人 vs 西班牙裔)和前列腺癌基线特征(前列腺特异性抗原、临床 T 期、Gleason 分组分级、活检核心阳性百分比)进行分层。我们列出了无基线年龄和前列腺癌特征调整以及调整后的积极治疗率(根治性前列腺切除术、外照射放疗)。
在有利和不利的中等风险前列腺癌患者中,根据种族/族裔,基线前列腺特异性抗原、临床 T 期、Gleason 分级和阳性活检核心百分比均存在差异(均 p <0.05)。同样,在有利和不利的中等风险前列腺癌患者中,根治性前列腺切除术和外照射放疗率也因种族/族裔而异。在有利的中等风险病例中,根治性前列腺切除术和外照射放疗率分别为 31.7%-41.8%和 26.3%-31.0%,在不利的中等风险前列腺癌中,分别为 33.4%-43.9%和 30.9%-35.5%,横跨 3 个种族/族裔群体(均 p <0.05)。在调整基线年龄和前列腺癌特征后,积极治疗率的上述差异消失,仅存在边缘差异。
除非对基线年龄和前列腺癌特征进行详细和系统的考虑或调整,否则对有利和不利的中等风险前列腺癌的积极治疗率的解释可能存在严重偏见。